Eli Lillys retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, remains in Phase 3 TRIUMPH trials as of mid-2026, with NDA submission projected no earlier than Q4 2026
Knowing that GLP-1 receptor agonists decrease gastric emptying, we do not know definitively whether they impact oral contraceptives
Kimberly-Clark to buy Tylenol maker Kenvue for US$40b Deal talks between the companies started after Kenvue announced it was reviewing strategic alternatives
If the PA request for a weight management agent is approved, a decision notice letter will be mailed to the provider
S-Acetyl-L-glutathione's ability to replenish glutathione levels makes it beneficial in supporting healthy aging and promoting cellular function while also aiding in improving liver function and enhancing immune response
Ask your doctor or pharmacist to show you how to dispose of used semaglutide pens properly in a puncture-resistant container